Regeneron Pharmaceuticals Inc was Intellia Therapeutics’s largest revenue line in fiscal 2019, bringing in $24.60M of $43.10M (57%).
| Counterparty Name | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | $8.70M | $16.80M | — | $24.60M | |
| Regeneron | — | — | $20.10M | — | |
| Novartis | $7.80M | $9.30M | $10.30M | $18.50M | |
| Total | $16.50M | $26.10M | $30.40M | $43.10M |
Intellia Therapeutics brought in $43.10M from its two revenue lines in fiscal 2019, the year ended December 31, 2019. Intellia Therapeutics regrouped these revenue lines after fiscal 2018, so the total does not compare directly with that year's $30.40M. Regeneron Pharmaceuticals Inc was the largest at $24.60M (57.1%), ahead of Novartis at $18.50M (42.9%).
From fiscal 2016 to 2019, combined revenue from these revenue lines grew from $16.50M to $43.10M, a compound annual growth rate of 37.7%. Regeneron Pharmaceuticals Inc's share of the total rose from 52.7% to 57.1%.
Intellia Therapeutics stopped reporting Regeneron as a separate revenue line after fiscal 2018, when it brought in $20.10M.
Intellia Therapeutics (NTLA) reports its revenue by counterparty name. In fiscal 2019, Regeneron Pharmaceuticals Inc was its largest revenue line, bringing in $24.60M (57.1% of the total), followed by Novartis at $18.50M (42.9%).
Regeneron Pharmaceuticals Inc was Intellia Therapeutics' largest revenue line in fiscal 2019, bringing in $24.60M, or 57.1% of the $43.10M total across its two revenue lines.
Every figure comes from Intellia Therapeutics' annual financial filings, as reported. Each line keeps the name Intellia Therapeutics gives it, and years follow its fiscal calendar.
Intellia Therapeutics' revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.